KEYNOTE-052: Updated Findings on First-line Pembrolizumab in Cisplatin-Ineligible Advanced Urothelial Cancer

June 2-6, 2017; Chicago, Illinois

ORR increased from previous report with longer follow-up and 18-gene GEP score significantly associated with response.

Format: Microsoft PowerPoint (.ppt)

File Size: 1.38 MB

Released: June 8, 2017

Acknowledgements

Supported by educational grants by

AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Cookie Settings